Isomorphic diffuse glioma is a morphologically and molecularly distinct tumour entity with recurrent gene fusions of MYBL1 or MYB and a benign disease course

[1]  David T. W. Jones,et al.  cIMPACT-NOW update 4: diffuse gliomas characterized by MYB, MYBL1, or FGFR1 alterations or BRAFV600E mutation , 2019, Acta Neuropathologica.

[2]  David T. W. Jones,et al.  Papillary glioneuronal tumor (PGNT) exhibits a characteristic methylation profile and fusions involving PRKCA , 2019, Acta Neuropathologica.

[3]  David T. W. Jones,et al.  FGFR1:TACC1 fusion is a frequent event in molecularly defined extraventricular neurocytoma , 2018, Acta Neuropathologica.

[4]  David T. W. Jones,et al.  Molecular heterogeneity and CXorf67 alterations in posterior fossa group A (PFA) ependymomas , 2018, Acta Neuropathologica.

[5]  David T. W. Jones,et al.  Primary intracranial spindle cell sarcoma with rhabdomyosarcoma-like features share a highly distinct methylation profile and DICER1 mutations , 2018, Acta Neuropathologica.

[6]  David T. W. Jones,et al.  Molecularly defined diffuse leptomeningeal glioneuronal tumor (DLGNT) comprises two subgroups with distinct clinical and genetic features , 2018, Acta Neuropathologica.

[7]  David T. W. Jones,et al.  Anaplastic astrocytoma with piloid features, a novel molecular class of IDH wildtype glioma with recurrent MAPK pathway, CDKN2A/B and ATRX alterations , 2018, Acta Neuropathologica.

[8]  Michael C. Heinold,et al.  The landscape of genomic alterations across childhood cancers , 2018, Nature.

[9]  David T. W. Jones,et al.  DNA methylation-based classification of central nervous system tumours , 2018, Nature.

[10]  S. Pfister,et al.  Pediatric low-grade gliomas: next biologically driven steps , 2018, Neuro-oncology.

[11]  Maria Thom,et al.  Histopathological Findings in Brain Tissue Obtained during Epilepsy Surgery , 2017, The New England journal of medicine.

[12]  Cheng Cheng,et al.  THE GENOMIC LANDSCAPE OF PEDIATRIC AND YOUNG ADULT T-LINEAGE ACUTE LYMPHOBLASTIC LEUKEMIA , 2017, Nature Genetics.

[13]  Martin Sill,et al.  DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis. , 2017, The Lancet. Oncology.

[14]  Y. Okuno,et al.  Recurrent MYB rearrangement in blastic plasmacytoid dendritic cell neoplasm , 2017, Leukemia.

[15]  F. Woermann,et al.  Mild Malformation of Cortical Development with Oligodendroglial Hyperplasia in Frontal Lobe Epilepsy: A New Clinico‐Pathological Entity , 2017, Brain pathology.

[16]  Roland Eils,et al.  New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs , 2016, Cell.

[17]  Heather L. Mulder,et al.  Genetic alterations in uncommon low-grade neuroepithelial tumors: BRAF, FGFR1, and MYB mutations occur at high frequency and align with morphology , 2016, Acta Neuropathologica.

[18]  Liliana Goumnerova,et al.  MYB-QKI rearrangements in Angiocentric Glioma drive tumorigenicity through a tripartite mechanism , 2016, Nature Genetics.

[19]  Steven J. M. Jones,et al.  Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. , 2015, The New England journal of medicine.

[20]  Volker Hovestadt,et al.  Adult IDH wild type astrocytomas biologically and clinically resolve into other tumor entities , 2015, Acta Neuropathologica.

[21]  Gary D Bader,et al.  Molecular Classification of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age Groups. , 2015, Cancer cell.

[22]  D. Louis,et al.  Letter in Response to David N. Louis et al, International Society of Neuropathology‐Haarlem Consensus Guidelines for Nervous System Tumor Classification and Grading, Brain Pathology, doi: 10.1111/bpa.12171 , 2014, Brain pathology.

[23]  Pieter Wesseling,et al.  International Society of Neuropathology‐Haarlem Consensus Guidelines for Nervous System Tumor Classification and Grading , 2014, Brain pathology.

[24]  David T. W. Jones,et al.  Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma , 2014, Acta Neuropathologica.

[25]  Eleonora Aronica,et al.  A neuropathology-based approach to epilepsy surgery in brain tumors and proposal for a new terminology use for long-term epilepsy-associated brain tumors , 2014, Acta Neuropathologica.

[26]  Miguel Maravall,et al.  Lineage-specific laminar organization of cortical GABAergic interneurons , 2013, Nature Neuroscience.

[27]  Roland Eils,et al.  Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma , 2013, Nature Genetics.

[28]  Benjamin J. Raphael,et al.  The Mutational Landscape of Adenoid Cystic Carcinoma , 2013, Nature Genetics.

[29]  Volker Hovestadt,et al.  Robust molecular subgrouping and copy-number profiling of medulloblastoma from small amounts of archival tumour material using high-density DNA methylation arrays , 2013, Acta Neuropathologica.

[30]  Liliana Goumnerova,et al.  Genomic analysis of diffuse pediatric low-grade gliomas identifies recurrent oncogenic truncating rearrangements in the transcription factor MYBL1 , 2013, Proceedings of the National Academy of Sciences.

[31]  Heather L. Mulder,et al.  Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas , 2013, Nature Genetics.

[32]  David T. W. Jones,et al.  Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. , 2012, Cancer cell.

[33]  Colin N. Dewey,et al.  RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome , 2011, BMC Bioinformatics.

[34]  P. Brousset,et al.  Identification of a transforming MYB-GATA1 fusion gene in acute basophilic leukemia: a new entity in male infants. , 2011, Blood.

[35]  Kirsten Schmieder,et al.  Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma , 2011, Acta Neuropathologica.

[36]  Helga Thorvaldsdóttir,et al.  Integrative Genomics Viewer , 2011, Nature Biotechnology.

[37]  S. Shurtleff,et al.  MYB upregulation and genetic aberrations in a subset of pediatric low-grade gliomas , 2010, Acta Neuropathologica.

[38]  H. Zentgraf,et al.  Characterization of R132H Mutation‐specific IDH1 Antibody Binding in Brain Tumors , 2010, Brain pathology.

[39]  R. McLendon,et al.  IDH1 and IDH2 mutations in gliomas. , 2009, The New England journal of medicine.

[40]  H. Horlings,et al.  Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neck , 2009, Proceedings of the National Academy of Sciences.

[41]  H. Zentgraf,et al.  Monoclonal antibody specific for IDH1 R132H mutation , 2009, Acta Neuropathologica.

[42]  Christian Mawrin,et al.  Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas , 2009, Acta Neuropathologica.

[43]  Alan M Gewirtz,et al.  The c-myb proto-oncogene and microRNA-15a comprise an active autoregulatory feedback loop in human hematopoietic cells. , 2009, Blood.

[44]  J. Schelter,et al.  c-Myb oncoprotein is an essential target of the dleu2 tumor suppressor microRNA cluster , 2008, Cancer biology & therapy.

[45]  David T. W. Jones,et al.  Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. , 2008, Cancer research.

[46]  H. Kuo,et al.  c-Myb is an evolutionary conserved miR-150 target and miR-150/c-Myb interaction is important for embryonic development. , 2008, Molecular biology and evolution.

[47]  Robert G. Ramsay,et al.  MYB function in normal and cancer cells , 2008, Nature Reviews Cancer.

[48]  N. Rajewsky,et al.  MiR-150 Controls B Cell Differentiation by Targeting the Transcription Factor c-Myb , 2007, Cell.

[49]  N. Rajewsky,et al.  MiR-150 Controls B Cell Differentiation by Targeting the Transcription Factor c-Myb , 2007, Cell.

[50]  H. Urbach,et al.  Correlation of MRI and histopathology in epileptogenic parietal and occipital lobe lesions , 2007, Seizure.

[51]  B. Scheithauer,et al.  The 2007 WHO Classification of Tumours of the Central Nervous System , 2007, Acta Neuropathologica.

[52]  H. Urbach,et al.  Evidence for a Clinically Distinct New Subtype of Grade II Astrocytomas in Patients with Long-term Epilepsy , 2004, Neurosurgery.

[53]  H. Urbach,et al.  An isomorphic subtype of long-term epilepsy-associated astrocytomas associated with benign prognosis , 2004, Acta Neuropathologica.

[54]  E. Reddy,et al.  The myb gene family in cell growth, differentiation and apoptosis , 1999, Oncogene.

[55]  K. Weston.  Myb proteins in life, death and differentiation. , 1998, Current opinion in genetics & development.

[56]  N. Nomura,et al.  Human A‐myb gene encodes a transcriptional activator containing the negative regulatory domains , 1995, FEBS letters.

[57]  A. Sarai,et al.  Transactivation and transformation by Myb are negatively regulated by a leucine-zipper structure. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[58]  T. Gonda,et al.  Activation of c‐myb by carboxy‐terminal truncation: relationship to transformation of murine haemopoietic cells in vitro. , 1989, The EMBO journal.

[59]  Stefan M. Pfister,et al.  Routine RNA sequencing of formalin-fixed paraffin-embedded specimens in neuropathology diagnostics identifies diagnostically and therapeutically relevant gene fusions , 2019, Acta Neuropathologica.

[60]  G. Reifenberger,et al.  Sellar Region Atypical Teratoid/Rhabdoid Tumors (ATRT) in Adults Display DNA Methylation Profiles of the ATRT-MYC Subgroup , 2018, The American journal of surgical pathology.

[61]  David T. W. Jones,et al.  DNA methylation-based reclassification of olfactory neuroblastoma , 2018, Acta Neuropathologica.

[62]  D. Louis.  WHO classification of tumours of the central nervous system , 2007 .